<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081689</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 16/03_NADIM</org_study_id>
    <nct_id>NCT03081689</nct_id>
  </id_info>
  <brief_title>Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients</brief_title>
  <official_title>Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and
      efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W
      + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult
      patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months
      and Nivolumab 480mg Q4W for 8 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and
      efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W
      + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult
      patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months
      and Nivolumab 480mg Q4W for 8 months.

      Three cycles of neoadjuvant chemotherapy in combination with nivolumab will be administered.

      After completion of neoadjuvant therapy (3 cycles) and before surgery, a tumor assessment
      will be done. Patients have to leave the study if there is evidence of progression. Patients
      with in-stable disease or partial response may be considered for surgery.

      The report imaging response vs pathological response rate will be evaluated.

      Patients eligible for the trial are those with a histological diagnosis or cytologically
      proven operable and resectable non-small-cell lung cancer. The total number of patients to be
      included will be 46 from 23 participating sites in Spain.

      Accrual period of 1.5 years or until the inclusion of the last patient necessary to achieve
      the sample set in the protocol of 46 patients. After that all patients will be treated for 1
      year with adjuvant immunotherapy and they will be followed during 3 years after adjuvant
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 24 months from the first dose of neadjuvant treatment</time_frame>
    <description>The progression free survival is the time until the patients disease progresses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 years from the first dose of neoadjuvant treatment</time_frame>
    <description>Time when the patient is still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>from the first dose of neoadjuvant treatment until 90 days after the last dose of adjuvant treatment</time_frame>
    <description>Toxicities caused by the drug during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 360 mg</intervention_name>
    <description>Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 200mg/m2</intervention_name>
    <description>Paclitaxel 200mg/m2 IV Q3W</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 6</intervention_name>
    <description>Carboplatin AUC 6 IV Q3W</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects eligible for the study are those with histologically- or cytologically-
             documented NSCLC who present stage IIIA disease. Locally advanced patients who present
             stage IIIA by the previous version can be included if are considered potencially
             resectable. In case of N2 disease suspicion, pathological assessment by EBUS,
             mediastinoscopy or thoracotomy has to be carried out for N2 confirmation.

          2. Tumor should be considered resectable before study entry

          3. Performance Status of 0 or 1

          4. Screening laboratory values must meet the following criteria and should be obtained
             within 14 days prior to registration/inclusion i. WBC ≥ 2000/μL ii. Neutrophils ≥
             1500/μL iii. Platelets ≥ 100 x103/μL iv. Hemoglobin &gt; 9.0 g/dL v. Serum creatinine ≤
             1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault
             formula below): a. Female CrCl = (140 - age in years) x weight in kg x 0.85

        1. 72 x serum creatinine in mg/dL

        b. Male CrCl = (140 - age in years) x weight in kg x 1.00

          1. 72 x serum creatinine in mg/dL vi. AST/ALT ≤ 3 x ULN vii. Total Bilirubin ≤ 1.5 x ULN
             (except subjects with Gilbert Syndrome, who can have total bilirubin &lt; 3.0 mg/dL)
             viii. INR/APTT within normal limits

             5. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters

             6. All patients are notified of the investigational nature of this study and signed a
             written informed consent in accordance with institutional and nacional guidelines,
             including the Declaration of Helsinki prior to any trial-related intervention.

             7. Patients aged &gt; 18 years

             8. Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception.

             9. Women must not be breastfeeding

             10. Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year.

             Exclusion Criteria:

               1. All patients carrying activating mutations in the TK domain of EGFR or any
                  variety of alterations in the ALK gene.

               2. Patients with active, known or suspected autoimmune disease.

               3. Patients with a condition requiring systemic treatment with either
                  corticosteroids (&gt;10 mg daily prednisone equivalent) or other immunosuppressive
                  medications within 14 days of enrollment.

               4. Patients with a history of interstitial lung disease cannot be included if they
                  have sympthomatic ILD (Grade 3-4)

               5. Patients with other active malignancy requiring concurrent intervention

               6. Patients with previous malignancies (except non-melanoma skin cancers, and the
                  following in situ cancers: bladder, gastric, colon, endometrial,
                  cervical/dysplasia, melanoma, or breast) are excluded unless a

               7. Any medical, mental or psychological condition which in the opinion of the
                  investigator would not permit the patient to complete the study

               8. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,
                  anti-CTLA-4 antibody,

               9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or
                  hepatitis C virus ribonucleic acid (HCV antibody)

              10. Patients with known history of testing positive for human immunodeficiency virus
                  (HIV)

              11. Patients with history of allergy to study drug components excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>spanish Lun Cancer Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo hospitalario de la coruña</name>
      <address>
        <city>La Coruña</city>
        <state>Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36212</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Duran i Reynals-ICO</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Macrena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Gen. Univ. Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Web page of the sponsor where users can find more information about SLCG studies</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

